Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 1. Differences in smellprints between patients with lung cancer and breast cancer

Completed

Conditions: breast cancer
lung cancer or bronchial carcinoma
10006291
10029107

Registration Number: NL-OMON35264

Lead Sponsor: Medisch Centrum Leeuwarden

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

1. all women (18-80 yr) suspected of having breast cancer, referred to the OPD specialised in the diagnostic work-up of breast abnormalities in our hospital will be asked to participate (intention-to-diagnose). The first 25 patients with histologically confirmed breast cancer will be included in the analysis.
2. all patients (18-80 yr) suspected of having lung cancer, referred to the pulmonary OPD in our hospital will be asked to participate (intention-to-diagnose). The first 25 patients with histologically confirmed non-small cell lung cancer will be included in the analysis.
3. 25 women without breast cancer, matched with breast cancer patients above for age and smoking history, will be randomly selected from the intention-to-diagnose cohort.
4. 25 healthy controls, matched with the lung cancer patients above for sex, age, and smoking history, will be recruited from visitors and personel of our hospital, of course on voluntary base.

Exclusion Criteria

other pulmonary disease. diabetes mellitus. documented hypercholesterolemia. malignancy in past. Significant cardiovascular pathology. Presence of paradontitis, history of upper or lower respiratory tract infection in the past 4 weeks.
Pregnancy, eating (including chewing gum), drinking, smoking < 3 hours before measurements.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome parameter is the difference in smellprints provided by<br /><br>eNose between patients with lung cancer and breast cancer.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary outcomes are:<br /><br>- the difference in smellprints between women with and without breast cancer<br /><br>- the difference in smellprints between patients with non-small cell lung<br /><br>cancer and healthy controls<br /><br>- the difference in smellprints between patients before and twice after<br /><br>resection of the lung tumour (at 1 and 6 weeks post-resection)</p><br>